JP2023520205A5 - - Google Patents

Info

Publication number
JP2023520205A5
JP2023520205A5 JP2022559575A JP2022559575A JP2023520205A5 JP 2023520205 A5 JP2023520205 A5 JP 2023520205A5 JP 2022559575 A JP2022559575 A JP 2022559575A JP 2022559575 A JP2022559575 A JP 2022559575A JP 2023520205 A5 JP2023520205 A5 JP 2023520205A5
Authority
JP
Japan
Prior art keywords
immune cells
effector immune
mhc class
effector
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022559575A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520205A (ja
Filing date
Publication date
Priority claimed from GBGB2005216.3A external-priority patent/GB202005216D0/en
Application filed filed Critical
Publication of JP2023520205A publication Critical patent/JP2023520205A/ja
Publication of JP2023520205A5 publication Critical patent/JP2023520205A5/ja
Priority to JP2025076879A priority Critical patent/JP2025107358A/ja
Priority to JP2025082745A priority patent/JP2025122064A/ja
Pending legal-status Critical Current

Links

JP2022559575A 2020-04-08 2021-04-08 細胞 Pending JP2023520205A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2025076879A JP2025107358A (ja) 2020-04-08 2025-05-02 細胞
JP2025082745A JP2025122064A (ja) 2020-04-08 2025-05-16 細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2005216.3 2020-04-08
GBGB2005216.3A GB202005216D0 (en) 2020-04-08 2020-04-08 Cell
PCT/GB2021/050862 WO2021205172A1 (en) 2020-04-08 2021-04-08 Cell

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025076879A Division JP2025107358A (ja) 2020-04-08 2025-05-02 細胞

Publications (2)

Publication Number Publication Date
JP2023520205A JP2023520205A (ja) 2023-05-16
JP2023520205A5 true JP2023520205A5 (https=) 2024-02-21

Family

ID=70768915

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022559575A Pending JP2023520205A (ja) 2020-04-08 2021-04-08 細胞
JP2025076879A Pending JP2025107358A (ja) 2020-04-08 2025-05-02 細胞
JP2025082745A Pending JP2025122064A (ja) 2020-04-08 2025-05-16 細胞

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2025076879A Pending JP2025107358A (ja) 2020-04-08 2025-05-02 細胞
JP2025082745A Pending JP2025122064A (ja) 2020-04-08 2025-05-16 細胞

Country Status (8)

Country Link
US (2) US20230148144A1 (https=)
EP (2) EP4132567A1 (https=)
JP (3) JP2023520205A (https=)
CN (1) CN115348869A (https=)
AU (1) AU2021251459A1 (https=)
CA (1) CA3174659A1 (https=)
GB (1) GB202005216D0 (https=)
WO (2) WO2021205173A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3120563A1 (en) 2018-11-26 2020-06-04 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
CN117511882A (zh) * 2022-08-03 2024-02-06 浙江大学医学院附属第一医院 一种通用型免疫效应细胞及其制备方法和应用
CN115747166B (zh) * 2022-10-13 2024-12-06 上海怡豪生物科技有限公司 一种通用型car-t细胞及其制备方法与应用
EP4608856A1 (en) * 2022-10-27 2025-09-03 CARGO Therapeutics, Inc. Compositions and methods for improved immunotherapies
CN121586777A (zh) * 2023-07-26 2026-02-27 上海邦耀生物医药有限公司 用于治疗疾病的方法和组合物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
WO2000063374A1 (en) 1999-04-16 2000-10-26 Celltech Therapeutics Limited Synthetic transmembrane components
CA2538141A1 (en) 2003-09-09 2005-03-17 Gpc Biotech Ag Therapeutic human anti-mhc class ii antibodies and their uses
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
DK3241561T3 (da) 2014-03-05 2025-06-30 Autolus Ltd Konjugeret antistof eller bispecifik t-celle-engager, som selektivt binder enten tcr-beta konstant region 1 (trbc1) eller trbc2
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
SG10201913782UA (en) * 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cll-1 chimeric antigen receptor
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
GB201501936D0 (en) 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
GB201503742D0 (en) 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
GB201504840D0 (en) 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
US10294304B2 (en) * 2015-04-13 2019-05-21 Pfizer Inc. Chimeric antigen receptors targeting B-cell maturation antigen
US20200085871A1 (en) * 2017-03-17 2020-03-19 University Of Tennessee Research Foundation Methods of using cytotoxic t cells for treatment of autoimmune diseases
GB201709203D0 (en) 2017-06-09 2017-07-26 Autolus Ltd Antigen-binding domain
CN111315769A (zh) * 2017-09-06 2020-06-19 加州理工学院 信号传导和抗原呈递双功能受体(sabr)
GB201716728D0 (en) * 2017-10-12 2017-11-29 Autolus Ltd Cell
MX2020011254A (es) * 2018-04-27 2020-11-12 Crispr Therapeutics Ag Celulas t car anti-bcma para agotamiento de celulas de plasma.
WO2019220109A1 (en) 2018-05-15 2019-11-21 Autolus Limited Chimeric antigen receptor
IL281428B2 (en) 2018-09-27 2024-10-01 Autolus Ltd Chimeric antigen receptor
GB201817822D0 (en) 2018-10-31 2018-12-19 Autolus Ltd Binding domain
MX2021011816A (es) * 2019-03-29 2021-10-22 Univ Texas Metodos para produccion de celulas car-nk y uso de las mismas.

Similar Documents

Publication Publication Date Title
JP2023520205A5 (https=)
US20220281944A1 (en) Spycatcher and spytag: universal immune receptors for t cells
Govers et al. T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing
JP7566628B2 (ja) キメラ抗原受容体を発現する免疫細胞
US20170342124A1 (en) Universal Immune Receptor Expressed by T Cells for the Targeting of Diverse and Multiple Antigens
US12161668B2 (en) T cells expressing a chimeric antigen receptor
CA3125345A1 (en) Anti-tcr antibody molecules and uses thereof
JP2019525771A5 (https=)
JP2021529559A (ja) グルコース輸入を向上させるトランス代謝分子と組み合わせたキメラ受容体及びその治療的使用
JP7723420B2 (ja) Ｂ細胞標的化並列ＣＡＲ（ｐＣＡＲ）治療的薬剤
TW201904997A (zh) 引導及導航控制蛋白質以及彼之製造及使用方法
CN108513576A (zh) 可调变体免疫球蛋白超家族结构域和工程改造的细胞治疗
CA3002751A1 (en) Methods for culturing cells and kits and apparatus for same
RU2018109426A (ru) Химерные антигенные рецепторы со встроенными контролируемыми функциями
RU2020109577A (ru) Клетка
Kwong et al. Generation, affinity maturation, and characterization of a human anti-human NKG2D monoclonal antibody with dual antagonistic and agonistic activity
US12534509B2 (en) Engineered immune cells with receptor cross-talk
CN115348869A (zh) 细胞
JP2022527162A5 (https=)
WO2022195241A1 (en) Cd160 binding domain
Asby Expression of a Chimeric Coreceptor Enhances the Antitumor Immunity of CD22-Targeted CAR-T Cells
JP2025524457A (ja) 哺乳動物におけるキメラ抗原受容体介在性の免疫応答を刺激するための方法において使用するためのｃｄ１２３に対する標的化モジュール